<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669262</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-DXP604-101</org_study_id>
    <nct_id>NCT04669262</nct_id>
  </id_info>
  <brief_title>BGB-DXP604 Alone and in Combination With BGB DXP593 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BGB-DXP604 Alone and in Combination With BGB DXP593 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the safety and tolerability of&#xD;
      BGB-DXP604 alone and in combination with BGB-DXP593 in healthy participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Actual">May 21, 2021</completion_date>
  <primary_completion_date type="Actual">May 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 12-lead electrocardiogram (ECG) corrected QT (QTc) Interval</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing clinical laboratory abnormalities</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BGB-DXP593</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BGB-DXP604</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve until time t (AUCt) of BGB-DXP593</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve until time t (AUCt) of BGB-DXP604</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve extrapolated to infinity (AUCinf) of BGB-593</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve extrapolated to infinity (AUCinf) of BGB-DXP604</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve from zero to 29 days (AUC0-29) of BGB-DXP593</measure>
    <time_frame>Up to 29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve from zero to 29 days (AUC0-29) of BGB-DXP604</measure>
    <time_frame>Up to 29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve maximum observed plasma concentration (tmax) of BGB-DXP593</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve maximum observed plasma concentration (tmax) of BGB-DXP604</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life time (t1/2) of BGB-DXP593</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life time (t1/2) of BGB-DXP604</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of BGB-DXP593</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of BGB-DXP604</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz) of BGB-DXP593</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz) of BGB-DXP604</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical immunogenicity of BGB-DXP604 and BGB-DXP593 evaluated through the detection of anti-drug antibodies (ADAs) over time</measure>
    <time_frame>Up to 16 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: BGB-DXP604</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1A: Single low dose of BGB-DXP604 or placebo Part 1B: Single high dose of BGB-DXP604 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 : BGB-DXP604 + BGB-DXP593</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of BGB-DXP593 followed by a single dose of BGB-DXP604 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-DXP604</intervention_name>
    <description>Administered as intravenous (IV) infusion over 30 to 60 minutes</description>
    <arm_group_label>Part 1: BGB-DXP604</arm_group_label>
    <arm_group_label>Part 2 : BGB-DXP604 + BGB-DXP593</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-DXP593</intervention_name>
    <description>Administered as intravenous (IV) infusion over 30 to 60 minutes</description>
    <arm_group_label>Part 2 : BGB-DXP604 + BGB-DXP593</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match BGB-DXP593</description>
    <arm_group_label>Part 1: BGB-DXP604</arm_group_label>
    <arm_group_label>Part 2 : BGB-DXP604 + BGB-DXP593</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match BGB-DXP604</description>
    <arm_group_label>Part 2 : BGB-DXP604 + BGB-DXP593</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Participants are in good general health as determined by the investigator or medically&#xD;
             qualified designee, based on a medical evaluation including medical history, physical&#xD;
             examination, laboratory tests, and cardiac monitoring&#xD;
&#xD;
          2. Body weight â‰¥ 50 kg and body mass index (BMI) within the range 18 to 32 kg/m2&#xD;
             (inclusive)&#xD;
&#xD;
          3. Negative SARS-CoV-2 serology test&#xD;
&#xD;
          4. Negative for COVID-19 based on the nasopharyngeal or oropharyngeal swab with the&#xD;
             method of real-time reverse transcription-polymerase chain reaction (rRT-PCR)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Medical Histories or Conditions&#xD;
&#xD;
          1. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrinological, hematological, or neurological disorders capable of significantly&#xD;
             altering the absorption, metabolism, or elimination of drugs, constituting a risk to&#xD;
             the participant when receiving the study drug; or interfering with the interpretation&#xD;
             of data&#xD;
&#xD;
          2. Any malignancy within the past 5 years except for basal cell or squamous epithelial&#xD;
             carcinomas of the skin that has been resected with no evidence of metastatic disease&#xD;
             for 3 years&#xD;
&#xD;
          3. Any history of a severe allergic reaction before enrollment that has a reasonable risk&#xD;
             of recurrence during the study&#xD;
&#xD;
          4. Any chronic or clinically significant medical condition that, in the opinion of the&#xD;
             investigator, would jeopardize the safety or rights of the participant, including but&#xD;
             not limited to type 1 diabetes mellitus, chronic hepatitis; or clinically significant&#xD;
             forms of: drug or alcohol abuse, asthma (except for childhood asthma), autoimmune&#xD;
             disease, psychiatric disorders, or heart disease&#xD;
&#xD;
          5. Previous receipt of a licensed or investigational biologic agent (such as monoclonal&#xD;
             antibodies) within 3 months or 5 half-lives (whichever is longer) before the&#xD;
             randomization&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Yao, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q Pharm Pty Limited</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

